Inovio Pharmaceuticals, Inc. (INO)

Overview

Inovio Pharmaceuticals, Inc. is a prominently focused biotechnology firm that dedicates its research and development capabilities to the creation of innovative DNA medicines. These medicines are designed to offer treatments and preventive solutions for diseases associated with human papillomavirus (HPV), various cancer types, and a range of infectious diseases. Leveraging its revolutionary DNA medicines platform, the company excels in designing SynCon antigens that target specific DNA sequences of diseases optimally. Additionally, Inovio makes use of its CELLECTRA smart devices technology, which enhances the delivery of DNA plasmids directly into the body, ensuring efficient and targeted therapy. Founded in 1983, the company is headquartered in Plymouth Meeting, Pennsylvania, reflecting its longstanding commitment to advancing biotechnology and healthcare.

Products and Services

• VGX-3100:

  Developed for treating HPV-related cervical high-grade dysplasia, demonstrating Inovio’s focus on targeting HPV-induced conditions.

• INO-3107:

  Currently under Phase 1/2 trial, this product targets HPV-related recurrent respiratory papillomatosis, showcasing the company’s dedication to addressing less common but impactful HPV-related diseases.

• INO-3112:

  Focused on the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and currently under Phase 2 trial, highlighting the company’s venture into cancer treatment influenced by HPV.

• INO-5401:

  Designed for the treatment of glioblastoma multiforme and currently under Phase 2 trial. This immunotherapy approach underscores Inovio's commitment to tackling one of the most aggressive and difficult to treat forms of brain cancer.

• INO-4201:

  Targeting Ebola Virus Disease and under Phase 1b trial, reflecting Inovio’s efforts in combating highly infectious and deadly diseases with cutting-edge DNA medicine techniques.

• INO-4800:

  A COVID-19 vaccine candidate that is presently under Phase 3 trial, showing Inovio’s rapid response to global pandemic threats through innovative DNA vaccine development.

• INO-6160:

  Set to tackle human immunodeficiency virus (HIV) and is currently under Phase 1 trial. It represents Inovio’s ambitious project to address one of the most challenging infectious diseases affecting humanity today.

Inovio’s extensive pipeline reflects its comprehensive approach towards preventing and treating a wide array of diseases through DNA medicine. The company’s collaborations with various reputable organizations such as Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, and many others demonstrate its global commitment and interconnectedness in the fight against diseases.